Volume 35, Issue 6 pp. 490-501
RESEARCH ARTICLE

Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: A 3-year population-based longitudinal study

Daniel Feingold PhD

Corresponding Author

Daniel Feingold PhD

Psychology Department, Ariel University, Ariel, Israel

Lev-Hasharon Medical Center, Pardesiya, Israel

Correspondence

Daniel Feingold, Lev-Hasharon Medical Center, Pardesiya, Israel.

Email: [email protected]

Search for more papers by this author
Jürgen Rehm PhD

Jürgen Rehm PhD

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

Klinische Psychologie & Psychotherapie, Technische Universität Dresden, Dresden, Germany

Search for more papers by this author
Hagai Factor MA

Hagai Factor MA

Masters Program, Psychology Department, Ariel University, Ariel, Israel

Search for more papers by this author
Avigayil Redler MA

Avigayil Redler MA

Masters Program, Psychology Department, Ariel University, Ariel, Israel

Search for more papers by this author
Shaul Lev-Ran MD

Shaul Lev-Ran MD

Lev-Hasharon Medical Center, Pardesiya, Israel

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Search for more papers by this author
First published: 27 February 2018
Citations: 21

Abstract

Background

Cannabis use has been reported to negatively affect the course and outcome of various psychiatric disorders, yet little is known on its effect on rates of remission from anxiety disorders and associated clinical and functional outcomes.

Methods

In this study, data were drawn from Waves 1 and 2 of the National Epidemiologic survey on Alcohol and Related Conditions, focusing on individuals who qualified for a diagnosis of any anxiety disorder (social anxiety, panic disorder, generalized anxiety disorder, and specific phobias) at Wave 1 (N = 3,723). Cannabis users and individuals with cannabis use disorders (CUDs) throughout a 4-year period were compared to nonusers in rates of remission, suicidality, general functioning, and quality of life at Wave 2, while controlling for baseline confounders.

Results

Although rates of remission decreased with level of cannabis use, this was not maintained in adjusted models. Aside from specific outcomes (individuals with CUDs were significantly more prone to report breaking up from a romantic relationship; adjusted odds ratio [AOR] = 3.85, 95% confidence interval [CI] = 1.66–8.97) and repeatedly quitting school (AOR = 6.02, 95% CI = 2.65–13.66)), following adjustment no additional differences were found in outcome measures.

Conclusions

These findings add to previous reports suggesting that poorer outcome of anxiety disorders among cannabis users may be attributed mainly to differences in baseline factors and not cannabis use.

CONFLICT OF INTEREST

All authors declare that they have no conflicts of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.